5 Most Promising Cancer Stocks According to Analysts

Page 1 of 5

In this article, we discuss 5 most promising cancer stocks according to analysts. If you want to see more stocks in this selection, check out 11 Most Promising Cancer Stocks According to Analysts

5. BeiGene, Ltd. (NASDAQ:BGNE)

Number of Hedge Fund Holders: 15

Average Price Target Based on Analyst Ratings: 46.64% 

BeiGene, Ltd. (NASDAQ:BGNE) is a Massachusetts-based biotechnology company that focuses on discovering, developing, and commercializing medicines worldwide. The company has a portfolio of medicines for colorectal cancer, liver cancer, non-small cell lung cancer, endometrial cancer, solid and hematological cancers, breast cancer, and gastric cancer, among others. BeiGene, Ltd. (NASDAQ:BGNE) announced that cash, cash equivalents, restricted cash, and short-term investments were $4.5 billion as of December 31, 2022, compared to $6.6 billion as of December 31, 2021.

On January 20, Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene, Ltd. (NASDAQ:BGNE) to $350 from $290 and kept a Buy rating on the shares. This is in response to the announcement by the company that the FDA has approved Brukinsa for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in adult patients, the analyst told investors. 

According to Insider Monkey’s fourth quarter database, 15 hedge funds were long BeiGene, Ltd. (NASDAQ:BGNE), compared to 18 funds in the prior quarter. Julian Baker and Felix Baker’s Baker Bros. Advisors is the largest stakeholder of the company, with 11.6 million shares worth $2.5 billion. 

Here is what Longleaf Partners Asia Pacific UCITS Fund has to say about BeiGene, Ltd. (NASDAQ:BGNE) in its Q1 2022 investor letter:

“One company that we do not hold, but that serves as a good example of corrective action, is BeiGene (NASDAQ:BGNE). The company recently switched auditors to Ernst & Young USA from Ernst & Young China for its US Securities and Exchange Commission (SEC) audit reports to avoid a delisting in the US.”

Follow Beigene Ltd. (NASDAQ:BGNE)

Page 1 of 5